Catalyst Event
D&D Pharmatech Inc (347850) · Other
From KRX Bio Technology Transfer Index (KBIOTT)
3/24/2026, 12:00:00 AM
Three key US-based co-founders exercised their stock options on 2026-03-24, signaling strong confidence in the company's long-term growth prospects; low impact estimated as a positive internal signal.
Korean Translation
2026년 3월 24일 미국 주요 공동 창업자 3인이 주식매수선택권(스톡옵션)을 행사하며 성장에 대한 확신을 표명함. 긍정적 내부 신호로 낮은 영향이 예상됨.
Related Recent Events
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA ADC pipeline candidates at the American Association for Cancer Research (AACR) 2026 annual meeting scheduled
4/17/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
The 16th annual general shareholders' meeting is scheduled for March 31, 2026. Key agenda items include the appointment of directors, with potential for a proxy fight amid a renewed management dispute between major shareholders and current management. High impact is estimated as management disputes often lead to significant price volatility scheduled
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
The 20th Annual General Meeting of Shareholders including approval of financial statements and appointment of a new director scheduled
3/31/2026, 12:00:00 AM
OliX Pharmaceuticals Inc (226950) · Other
Announcement of positive preclinical results for obesity treatment OLX501A showing 84% ALK7 gene suppression in primates and plans to accelerate development expected. High efficacy in primate studies is estimated to result in a price impact of over 5%, expected.
3/24/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Approval from the Ministry of Food and Drug Safety to add 'back pain' as an indication for the NSAID combination drug 'Naxozol' is expected on March 24, 2026. Low impact is estimated as this is an incremental update to an existing product scheduled
3/24/2026, 12:00:00 AM
GC Cell Corporation (144510) · Other
The 15th Annual General Meeting of Shareholders was held on March 24, 2026, where the approval of financial statements and the re-appointment of an internal director were resolved.
3/24/2026, 12:00:00 AM